King Abdulaziz University

Virginia Commonwealth University

The Children's Hospital of Philadelphia

Illexcor Holdings, LLC

Moustafa Elsayed El-Araby

Abdelsattar Mansour Omar

Martin K Safo

Azizah M Malebari

Maan Talaat Khayat

Farid Ahmed

Ashraf B Abdel-Naim

Dhaval Shah

Radwan S Elhaggar

Mostafa H Ahmed

Ahmed Esmat

Tamer M Abdelghany

Thikryat Neamatallah

Mohamed A El-Zahabi

Salah G Atteiah

Osheiza Abdulmalik

Hani Zakariah Asfour

Mahmoud A Elfaky

Khadijah A Mohammad

Faida Hassan Bamane

Mohamed Moustafa Hawwas

Ghufran A Alhowswi

Fatma M Alhaity

Muna M Albeeshy

Mahmoud Abdelkhalek El-Faky

Tarek Salah Ibrahim

Sameh Hamdy Abdelmageed Soror

Yan Zhang

Yosra A Muhammad

Khaled Abouzid

Maiy Jaballah

Mohammad Imran Khan

Andrew Fleischman

David Light

Abdelsatter M Omar

Mahmood Hassan Dalhat

Mohammed Razeeth S Mohammed

Majed Abdullah A Alharbi

Hani Mohammed Z Choudhry

Amer Hamzah O Asseri

Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are chemically modified to increase bioavailability and activity, e.g., so that the compounds prevent adhesion and sickling of red blood cells (RBCs).

Benzaldehyde compounds with direct polymer destabilizing effects to treat sickle cell disease

Anti-microbial compounds having a pyridazine nucleus are provided. The compounds have anti-microbial (anti-biotic) properties and are used to treat infections caused by microbes, especially bacteria that are resistant to known antibiotics e.g. drug resistant bacteria such as methicillin-resistant(MRSA).

Potent antimicrobial compounds with a pyridazine nucleus

Therapeutic compounds containing an arylacetamide core pending N-benzyl group. Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for inhibiting AMP-activated kinase (AMPK) and their use thereof for treating breast and pancreatic cancer with the specified compounds.

Arylacetamides as AMP-activated protein kinase inhibitors and their use for treatment of breast cancer

Methods for administering compounds provide a rapid treatment for sickle cell disease (SCD) to inhibit or reverse red blood cell sickling. The compounds are a group of 5-hydroxymethylfurfural (5-HMF) analogs modified to increase water-solubility. The compounds can be formulated in an aqueous carrier and administered intravenously for immediate uptake into red blood cells (RBCs) within hours, rather than days or weeks. In vitro experiments demonstrated rapid uptake into RBCs and increased Oaffinity of HbS to an equilibrium point within 30 to 90 minutes. The compounds have a desired level of safety as well as a short half-life, both of which are compatible with acute usage. Thus, the methods of treatment rapidly achieve therapeutic steady-state drug levels, making it possible to deliver a treatment in critical emergency care situations to prevent, reverse and otherwise treat acute sickling or anemia.

Methods for using 5-HMF analogs with increased solubility to inhibit or reverse RBC sickling

3-vinylquinolines analogs and methods of synthesizing the derivatives/analogs are provided. In particular, the compounds are useful for the treatment of cancer.

3-vinylquinolines as cancer cells inhibitors

Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.

Method for treating stomach cancer

A compound of formula (I), wherein Ris an optionally substituted aryl or an optionally substituted heteroaryl, Ris an optionally substituted aryl or an optionally substituted heteroaryl, and Ris an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.

Method for making propenamide compound

Method for treating a patient having a colon cancer

Cytotoxic compounds containing a phenyl core, amide link(s), an imidazolinone or a propenamide moiety. Also described are pharmaceutical compositions incorporating the cytotoxic compounds and methods for treating cancer. These compounds are cytotoxic against breast, prostate, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.

Chemotherapeutic oxazolone derivatives and pharmaceutical compositions thereof

Method for making anti-cancer compounds

Method of treating colorectal cancer

Anticancer compounds, pharmaceutical compositions thereof, and a method of treating cancer

Anti-cancer compounds having oxazolone derivation

Bis-propenamide compounds and methods of treating cancer

Pharmaceutical composition for treating cancer

Growing community of inventors

Jeddah, Saudi Arabia

Moustafa Elsayed El-Araby